Alfonso Maria D’Arco

Author

Istituti di Ricovero e Cura a Carattere Scientifico

Also Known As

A D'Arco, A M D'Arco, A. D'Arco, A. M. D'Arco, A. d'Arco, A.M. D'Arco, A.M. D'arco, A.M. D’Arco, Alfonso D'Arco, Alfonso D'arco

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata Ospedale Policlinico San Martino Sapienza University of Rome Università degli Studi del Piemonte Orientale “Amedeo Avogadro”

About

Alfonso Maria D’Arco is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.2K
2	Health Sciences	5	5	356
3	Blood Transplantation	1	1	334
4	Classical Hematology	1	1	334
5	Emergency Medicine	1	1	17

Alfonso Maria D’Arco

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, Journal of Clinical Oncology	2016	375
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study Livio Pagano, Caterina Giovanna Valentini, Alessandro Pulsoni, Haematologica Mixed-phenotype Acute LeukemiaImmunologyPathologyClinical FeaturesImmunotherapy	2012	334
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi Luca Arcaini, Daniele Vallisa, Sara Rattotti, Annals of Oncology Lymphoid NeoplasiaAntiviral TreatmentViral HepatitisHematologyImmunology	2014	169
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi Stefano Luminari, Irène Biasoli, Luca Arcaini, Annals of Oncology Lymphoid NeoplasiaMedicineFollicular LymphomaPathologyInitial Staging	2013	150
Azacitidine for the treatment of patients with acute myeloid leukemia Luca Maurillo, Adriano Venditti, Alessandra Spagnoli, Cancer	2011	144
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaRadiation OncologyTransplantationRituximab-dose-dense Chemotherapy	2017	129
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial Andrés J.M. Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, Journal of Clinical Oncology	2015	115
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia Giovanni D’Arena, Luca Laurenti, Silvana Capalbo, American Journal of Hematology	2006	103
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi Michele Merli, Carlo Visco, Michele Spina, Haematologica	2013	80

Page 1